| Title |
Advances in Therapy for Pediatric Sarcomas
|
|---|---|
| Published in |
Current Oncology Reports, June 2014
|
| DOI | 10.1007/s11912-014-0395-z |
| Pubmed ID | |
| Authors |
Aaron Weiss, Jonathan Gill, John Goldberg, Joanne Lagmay, Holly Spraker-Perlman, Rajkumar Venkatramani, Damon Reed |
| Abstract |
Pediatric sarcomas are relatively rare malignancies individually. As a group they are typically approached with combination chemotherapies in addition to local control. Fortunately, these malignancies have been approached through careful clinical trial collaboration to define risk groups and appropriately deliver local control measures and systemic therapies. Although local disease is typically approached with curative intent, therapy typically lasts over 6 months and has significant associated morbidities. It is more difficult to cure metastatic disease or induce sustained remissions. In this article, we discuss recent advances in the understanding of the disease process and highlight recent and future cooperative group trials in osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, nonrhabdomyosarcoma soft tissue sarcomas, and desmoid tumor as well as discuss promising therapeutic approaches such as epigenetics and immunotherapy. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| France | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 35 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Portugal | 1 | 3% |
| Unknown | 34 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 8 | 23% |
| Student > Ph. D. Student | 5 | 14% |
| Student > Bachelor | 5 | 14% |
| Other | 4 | 11% |
| Student > Doctoral Student | 3 | 9% |
| Other | 9 | 26% |
| Unknown | 1 | 3% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 17 | 49% |
| Biochemistry, Genetics and Molecular Biology | 5 | 14% |
| Agricultural and Biological Sciences | 5 | 14% |
| Immunology and Microbiology | 2 | 6% |
| Unspecified | 1 | 3% |
| Other | 2 | 6% |
| Unknown | 3 | 9% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 January 2015.
All research outputs
#15,866,607
of 23,577,654 outputs
Outputs from Current Oncology Reports
#598
of 924 outputs
Outputs of similar age
#135,323
of 229,713 outputs
Outputs of similar age from Current Oncology Reports
#6
of 12 outputs
Altmetric has tracked 23,577,654 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 924 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.8. This one is in the 28th percentile – i.e., 28% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 229,713 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 31st percentile – i.e., 31% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.